Regeneron stock: UBS raises target for Regeneron stock to USD 978.00

Published on 10/19/2026 at 16:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron's results are due on October 30, 2026. Regeneron stock costs EUR 705.30 on October 19, 2026, down 0.11 percent versus the Xetra close.

Targets dates and valuation

UBS set a USD 978.00 target on October 15, 2026, after raising it from USD 660.00.
Regeneron will publish third-quarter results on October 30, 2026, before U.S. markets open.
Regeneron stock costs EUR 705.30 at Lang & Schwarz on October 19, 2026 at 4:07 p.m. CEST, 0.11 percent below the Xetra close of October 16, 2026.
Regeneron had a USD 81.4 billion market capitalization and a 19.61 P/E ratio as of October 19, 2026.

Architektur-Render eines modernen Glas- und Stahl-Forschungsgebäudes mit Vorplatz — Regeneron Pharma US75886F1075 zeigt ein architektonisches 3D-Render eines modernen Glas-Forschungsgebäudes mit gepflegten Grünflächen davor, Illustration mit AI erstellt.

UBS raised its price target for Regeneron Pharmaceuticals from USD 660.00 to USD 978.00 and upgraded the stock to Buy on October 15, 2026, according to Business Insider. The new target stands 23.73 percent above the USD 790.45 Nasdaq price at the October 19, 2026 finance snapshot. Regeneron stock was trading at EUR 705.30 at Lang & Schwarz on October 19, 2026 at 4:07 p.m. CEST, down 0.11 percent versus the Xetra close of October 16, 2026 at EUR 706.10.

October 30 results set the next test

Regeneron is scheduled to report third-quarter 2026 financial and operating results before U.S. markets open on October 30, 2026, with a conference call at 8:30 a.m. ET. The date was announced in a company release from September 24, 2026, published by Regeneron.

Stock stays below its yearly high

The Nasdaq-listed stock traded at USD 790.45 on October 19, 2026, compared with a 52-week range of USD 572.75 to USD 859.34. The current price is 8.02 percent below that high and 38.03 percent above the low. Regeneron was up 2.44 percent year to date through October 16, 2026.

Market value and valuation put the analyst target in a broader frame. Regeneron's market capitalization was USD 81.4 billion and its P/E ratio was 19.61 as of October 19, 2026. The company profile identifies Healthcare as its sector and Biotechnology as its industry, while its portfolio includes EYLEA, Dupixent and Libtayo.

Comparison with peers

Regeneron (Nasdaq, USD): minus 0.11 percent, P/E 19.61, market capitalization USD 81.4 billion.

Amgen (Nasdaq, USD): plus 0.20 percent, P/E 26.95, market capitalization USD 234.3 billion.

Gilead Sciences (Nasdaq, USD): plus 0.44 percent, P/E minus 58.87, market capitalization USD 194.5 billion.

Price position and valuation

The euro quotation remained close to the prior Xetra level, while the U.S. listing was 8.02 percent below its 52-week high. For investors, the October 30 reporting date and the USD 978.00 UBS target provide the two clearest dated markers for the next review of the stock.

Regeneron stock was trading at EUR 705.30 at Lang & Schwarz on October 19, 2026 at 4:07 p.m. CEST, 0.11 percent below the Xetra close of October 16, 2026 at EUR 706.10. The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.